My individual purchase in September. I normally stay away from penny stocks, but here I decided to invest for the following reasons:

Immutep is working on effective cancer treatments and therapies. Immutep has been able to record constant growth in recent years, 144% in 2020 alone, and reduce debt. The company is expected to be in the black by 2023. However, the strongest argument for me is that Immutep is currently testing therapeutics in clinical trials which, if approved in the USA, should lead to a jump in the share price (as is usually the case with approvals). In addition, the current share price is 122% below the target price of all medium-term analyses. No risk no fun.